Oklahoma OAC 252 Chapter 100. Air Pollution Control, Subchapter17. Incinerators, Part 4. Biomedical Waste Incinerators, SIP effective January 4, 2016 (OKd15)
Regulatory Text:
Oklahoma Administrative Code. Title 252. Department of Environmental Quality
Chapter 100. Air Pollution Control (OAC 252:100)
SUBCHAPTER 17. INCINERATORS (OAC 252:100-17)
PART 4. BIOMEDICAL WASTE INCINERATORS, SIP effective January 4, 2016 (OKd15),
As adopted in Oklahoma Register May 2, 2011 (28 Ok Reg 643) effective July 1, 2011,
Submitted to EPA January 18, 2013 (OK-46),
Regulations.gov document EPA-R06-OAR-2011-0034-0008 [OK017.08] Adobe file page 317-318.
Approved by EPA November 3, 2015 (80 FR 67647) effective January 4, 2016 (OKd15),
Regulations.gov docket EPA-R06-OAR-2011-0034 [OK017].
Sections:
252:100-17-8. Applicability, OKd15
252:100-17-9. Definitions, OKd15
252:100-17-10. Design and operation, OKd15
252:100-17-11. Emission limits, OKd15
252:100-17-8. Applicability
This part applies to any new or existing biomedical waste incinerator that is not subject to the requirements of Part 7 of this subchapter or is exempted from the requirements of Subpart Ec of 40 CFR Part 60.
252:100-17-9. Definitions
The following words and terms when used in this part shall have the following meaning unless the context clearly indicates otherwise:
"Antineoplastic agents" means drugs used to inhibit and combat the development of neoplasms.
"Biomedical radioactive waste" means low-level radioactive waste as defined in 40 CFR 60.51c.
"Biomedical waste" means medical/infectious waste as defined in 40 CFR 60.51c, Chemotherapeutic waste and biomedical radioactive waste.
"Biomedical waste incinerator" means an incinerator used to burn biomedical waste.
"Chemotherapeutic waste" means waste material resulting from the production or use of antineoplastic agents.
"Neoplasms" means tumors consisting of an abnormal proliferation of cells. The growth of this clone of cells exceeds, and is uncoordinated with, that of the normal tissues around it. Neoplasms may be benign, pre-malignant or malignant.
252:100-17-10. Design and operation
An incinerator subject to this part shall be designed and built with a primary combustion chamber and secondary combustion chamber(s) each equipped with burners or other combustion devices that maintain the applicable temperature and retention time specified in (1) through (3) of this section in both the primary and secondary combustion chamber(s) at all times when biomedical waste is being incinerated.
(1) The temperature in the primary combustion chamber shall not be less than 1,200 degrees F.
(2) The temperature in the secondary combustion chamber(s) shall not be less than 1,800 degrees F with a retention time of not less than one (1) second when processing biomedical waste containing no chemotherapeutic waste.
(3) The temperature in the secondary combustion chamber(s) shall not be less than 2,000 degrees F with a retention time of not less than two (2) seconds when processing biomedical waste containing chemotherapeutic waste.
252:100-17-11. Emission limits
Emissions from any biomedical waste incinerator subject to the requirements of this part shall not exceed the limits specified in (1) through (3) of this section. Any required performance testing shall be conducted while the incinerator is operating between 90% and 100% of operating capacity, or under other representative operating conditions specified by an applicable permit or testing method.
(1) Hydrochloric acid (HCl). Emissions of HCl shall not exceed 4.0 lb/hr.
(2) Particulate matter. Emissions of particulate matter shall not exceed 0.08 gr/dscf (grains per dry standard cubic foot) corrected to12% carbon dioxide in the emission gas stream.
(3) Carbon monoxide (CO). Emissions of CO shall not exceed 100 ppm by volume corrected to standard conditions in the emission gas stream.
***end 252:100 Subchapter 17 Part 4 SIP effective January 4, 2016 (OKd15)***z9a***